Cita APA

Herencia-Ropero, A., Llop Guevara, A., Staniszewska, A. D., Domènech-Vivó, J., García-Galea, E., Moles-Fernández, A., . . . Serra, V. (2024). The PARP1 selective inhibitor saruparib (AZD5305) elicits potent and durable antitumor activity in patient-derived BRCA1/2-associated cancer models.

Citación estilo Chicago

Herencia-Ropero, Andrea|||0009-0002-9448-1484, et al. The PARP1 Selective Inhibitor Saruparib (AZD5305) Elicits Potent and Durable Antitumor Activity in Patient-derived BRCA1/2-associated Cancer Models. 2024.

Cita MLA

Herencia-Ropero, Andrea|||0009-0002-9448-1484, et al. The PARP1 Selective Inhibitor Saruparib (AZD5305) Elicits Potent and Durable Antitumor Activity in Patient-derived BRCA1/2-associated Cancer Models. 2024.